Skip to main content

Open-Label Placebo Plus Treatment Rationale Effective for PMS

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 28, 2025.

via HealthDay

FRIDAY, March 28, 2025 -- Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ Evidence-Based Medicine.

Antje Frey Nascimento, from the University of Basel in Switzerland, and colleagues conducted a randomized controlled trial involving 150 women aged 18 to 45 years with PMS or premenstrual dysphoric disorder. Participants were randomly assigned to treatment as usual (TAU; 50 women), OLP without treatment rationale (OLP−; 50 women), or OLP with treatment rationale (OLP+; 50 women); OLP consisted of two placebo pills per day for six weeks.

The researchers found that across three menstrual cycles (MC1 to MC3), there was a difference between the groups in symptom intensity and interference. At MC3, mean symptom intensity was lower for OLP+ versus TAU and OLP− (b = −9.97 and −6.10), while no difference was seen between TAU and OLP−. At MC3, mean interference was lower for OLP+ than for TAU or OLP− (b = −1.23 and −1.10), with no difference between TAU and OLP−. There were reports of four nonserious adverse events in OLP− and OLP+ (one and three, respectively). High adherence was seen to the OLP intervention (93.18 ± 18.95 percent), with no between-group difference.

"Considering our results as much as the individual and societal burden of PMS, OLP treatment could serve as an acceptable, efficacious, and safe intervention for PMS," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Racialized Economic Segregation Linked to Advanced Cancer Diagnosis

FRIDAY, Aug. 1, 2025 -- People living in racially and economically segregated neighborhoods are more likely to be diagnosed with advanced-stage breast and cervical cancer...

New Subtype of Diabetes Identified in Sub-Saharan Africans, Black Americans

FRIDAY, Aug. 1, 2025 -- A new diabetes subtype has been identified in Sub-Saharan Africans and Black Americans, according to a study published online July 21 in The Lancet...

Changes in Missouri Law Linked to Increased Breast Cancer Screening Rates

THURSDAY, July 31, 2025 -- Changes in Missouri law expanding breast cancer screening coverage have led to increased screening rates among Medicaid patients and an increased...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.